Average Co-Inventor Count = 4.34
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Regeneron Pharmaceuticals, Inc. (9 from 1,343 patents)
2. Regeneran Pharmaceuticals, Inc. (2 from 49 patents)
11 patents:
1. 12344677 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
2. 12091460 - Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
3. 11633501 - Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
4. 11485793 - Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
5. 11453721 - Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
6. 11254752 - Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies
7. 11155633 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
8. 10941208 - Anti-MUC16 antibodies
9. 10772972 - Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
10. 10738130 - Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
11. 10179819 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof